Answers are grounded in this paper and cite their sources.
Background Up to 40% of patients with COPD have type 2 inflammation. Interleukin (IL)-4/IL-13 are key drivers of type 2 inflammation, contributing to mucus plug formation and reduced clearance, which are linked to worse disease outcomes. Dupilumab, an anti-IL4Rα antibody, has shown efficacy and safety in patients with COPD and type 2 inflammation. However, the mechanisms driving exacerbation reductions and improvements in lung function and symptoms remain unclear. We present the phase 4 AEOLUS trial design that will evaluate the impact of dupilumab on mucus plugs and airway characteristics in those patients. Methods AEOLUS ( clinicaltrials.gov identifier NCT07053423 ), a phase 4, randomised, double-blind, placebo-controlled, multinational trial, will randomise 218 former or current smokers (aged 40–85 years) with COPD on inhaled background therapy (2:1) to dupilumab 300 mg or placebo every 2 weeks for 24 weeks. Key inclusion criteria were post-bronchodilator forced expiratory volume in 1 s (FEV 1 ) to forced vital capacity ratio <0.70, FEV 1 30% predicted to <80% pred, screening blood eosinophil count ≥300 cells·μL −1 or ≥150 cells·μL −1 with a history of ≥300 cells·μL −1 in the previous year, two or more moderate exacerbations or one or more severe exacerbations in the previous year and mucus plug score ≥3 on computed tomography (CT). The primary end-point was week 24 change from baseline in CT-evaluated mucus plug score. Secondary end-points were week 24 change from baseline in mucus plug volume, distal airway wall thickness, oscillometry parameters and safety. Conclusion AEOLUS will evaluate the effect of dupilumab on airway characteristics (mucus, resistance and remodelling) in patients with COPD and type 2 inflammation.
No takes yet. Share an insight, caveat, or question.
Bhatt et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: